Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Tang et al

Ann Rheum Dis. 2024 Feb 15;83(3):e5. doi: 10.1136/ard-2023-225026.

¹ Barbara Volcker Center for Women and Rheumatic Diseases, Division of Rheumatology, Hospital for Special Surgery; Weill Cornell Medicine, New York, NY, USA.
² Vascular Medicine Division and Regional Diseases, Université de Lorraine, Inserm, DCAC, and CHRU-Nancy, F-54000, Nancy, France.
³ Department of General Medicine and Rheumatology, Middlemore Hospital, Auckland, New Zealand.
⁴ CIC Clinical epidemiology, CHRU Nancy, Inserm, Université de Lorraine, Nancy, France.
⁵ Department of Rheumatology, Brigham and Women's Hospital, Boston, MA, USA.
⁶ Barbara Volcker Center for Women and Rheumatic Diseases, Division of Rheumatology, Hospital for Special Surgery; Weill Cornell Medicine, New York, NY, USA [email protected].

No abstract available

Keywords: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Classification.

MeSH terms